- Home
- DEC vs HROW Comparison
DEC vs HROW Comparison
Compare DEC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | HROW |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.4M | 1.1B |
| IPO Year | 2022 | 2008 |
Fundamental Metrics
Financial Performance| Metric | DEC | HROW |
|---|---|---|
| Price | $14.47 | $28.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $20.43 | ★ $63.00 |
| AVG Volume (30 Days) | 545.8K | ★ 581.3K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 7.90% | N/A |
| EPS Growth | ★ 311.06 | 71.43 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,829,142,000.00 | N/A |
| Revenue This Year | $24.84 | $28.59 |
| Revenue Next Year | $33.22 | $53.17 |
| P/E Ratio | $12.89 | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $12.35 | $26.96 |
| 52 Week High | $18.90 | $54.98 |
Technical Indicators
Market Signals| Indicator | DEC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 37.48 |
| Support Level | $12.48 | $28.54 |
| Resistance Level | $14.95 | $35.87 |
| Average True Range (ATR) | 0.40 | 1.43 |
| MACD | 0.05 | 0.24 |
| Stochastic Oscillator | 60.87 | 38.55 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.